Abstract
Hepatitis C virus (HCV) infects an estimated 170 million people globally and persistent infection within the liver is the usual outcome of infection. The resulting liver disease leads to substantial morbidity and to date no vaccine exists. Furthermore the treatments available are frequently ineffective. A minority of those exposed will however successfully control the virus and the factors that dictate this remain elusive. The events that occur in the immediate and early phase post exposure are thought to play a crucial role in determining the outcome and virus specific T cells have a confirmed role in directing the immune response towards a successful outcome. An understanding of the T cell responses and the strategies, which allow the virus to evade these responses in the majority, is an essential prerequisite both for vaccine design and the development of therapeutic agents. We review here the characteristics of the cellular immune responses in acute infection and how the virus manages to undermine these responses and establish chronicity.
Keywords: T cell, acute hepatitis C, immunology, cell-mediated, escape mutation
Current Pharmaceutical Design
Title: Cellular Immunity and Acute Hepatitis C Infection
Volume: 14 Issue: 17
Author(s): K. Fitzmaurice and P. Klenerman
Affiliation:
Keywords: T cell, acute hepatitis C, immunology, cell-mediated, escape mutation
Abstract: Hepatitis C virus (HCV) infects an estimated 170 million people globally and persistent infection within the liver is the usual outcome of infection. The resulting liver disease leads to substantial morbidity and to date no vaccine exists. Furthermore the treatments available are frequently ineffective. A minority of those exposed will however successfully control the virus and the factors that dictate this remain elusive. The events that occur in the immediate and early phase post exposure are thought to play a crucial role in determining the outcome and virus specific T cells have a confirmed role in directing the immune response towards a successful outcome. An understanding of the T cell responses and the strategies, which allow the virus to evade these responses in the majority, is an essential prerequisite both for vaccine design and the development of therapeutic agents. We review here the characteristics of the cellular immune responses in acute infection and how the virus manages to undermine these responses and establish chronicity.
Export Options
About this article
Cite this article as:
Fitzmaurice K. and Klenerman P., Cellular Immunity and Acute Hepatitis C Infection, Current Pharmaceutical Design 2008; 14 (17) . https://dx.doi.org/10.2174/138161208784746806
DOI https://dx.doi.org/10.2174/138161208784746806 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Novel, Acidic CCR2 Receptor Antagonists: Lead Optimization
Letters in Drug Design & Discovery Pharmacotherapy for Premature Ejaculation
Current Drug Therapy The Bioactive Acidic Serine- and Aspartate-Rich Motif Peptide
Current Protein & Peptide Science TGF-Beta Type I Receptor (Alk5) Kinase Inhibitors in Oncology
Current Pharmaceutical Biotechnology Determinants of Treatment Outcomes for Hepatitis C Infection and the Path to Personalized Medicine
Current Pharmacogenomics and Personalized Medicine Telmisartan Promotes Potential Glucose Homeostasis in Stroke-Resistant Spontaneously Hypertensive Rats via Peroxisome Proliferator-Activated Receptor γ Activation
Current Neurovascular Research Gene Sets of Gene Ontology are More Stable Diagnostic Biomarkers than Genes in Oral Squamous Cell Carcinoma
Current Bioinformatics Therapeutic Targeting of Endothelial Dysfunction in Chronic Diabetic Complications
Recent Patents on Cardiovascular Drug Discovery Is there a Role for Cortisol in the Accumulation of Lipids in the Intima a Crucial Step of Atherogenesis?
Current Vascular Pharmacology MMP14 Regulates VEGFR3 Expression on Corneal Epithelial Cells
Protein & Peptide Letters Monitoring Circulating Nitric Oxide Levels in Infants with Bronchopulmonary Dysplasia for Disease Activity
Current Pediatric Reviews Gender Disparity in Pediatric Diseases
Current Molecular Medicine Targeting Blood Vessels for the Treatment of Non-Small Cell Lung Cancer
Current Cancer Drug Targets Identification and Characterization of a Chemical Compound that Inhibits Methionyl-tRNA Synthetase from <i>Pseudomonas aeruginosa</i>
Current Drug Discovery Technologies Anticancer Activity of Bisphosphonates in Breast Cancer
Anti-Cancer Agents in Medicinal Chemistry Peroxisome Proliferator-Activated Receptor (PPAR)β /δ: A New Potential Therapeutic Target for the Treatment of Metabolic Syndrome
Current Molecular Pharmacology Polypeptide Delivery Across The Blood-Brain Barrier
Current Drug Targets - CNS & Neurological Disorders Design, Synthesis and Molecular Docking Studies of Novel Thiadiazole Analogues with Potential Antimicrobial and Antiinflammatory Activities
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Down Regulation of Differentiated Embryo-Chondrocyte Expressed Gene 1 is Related to the Decrease of Osteogenic Capacity
Current Drug Targets Meet Our Editorial Board Member
Recent Patents on Inflammation & Allergy Drug Discovery